Request for Information: CPE CBRND Seeking Device Capable of Delivering Medical Countermeasure via Inhalation and Intramuscular Routes
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Joint Project Manager (JPM) for CBRN Medical, under the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), is conducting market research through a Request for Information (RFI). The purpose is to identify industry capabilities for developing, testing, and manufacturing a device capable of delivering nalmefene via both inhalation (INH)/intranasal (IN) and intramuscular (IM) routes. This RFI seeks innovative solutions for both prophylactic and therapeutic medical countermeasures (MCMs) and explores alternative delivery methods within a single device. Responses are due by April 3, 2026.
Scope of Work / Key Requirements
- Device Capability: Must deliver nalmefene via INH/IN and IM routes.
- Dual Use: Designed for eventual U.S. Food and Drug Administration (FDA) approval as both a therapeutic and prophylactic product and a medical device.
- Ruggedization: Device must be ruggedized and compliant with military (MIL) standards for IM and IN/INH delivery.
- Innovation: Exploration of alternative methods to deliver both prophylactic and therapeutic MCMs in one device.
Submission & Timeline
- Type: Request for Information (RFI) / Sources Sought
- Response Due: April 3, 2026, 12:00 PM ET
- Published: March 20, 2026
- Submission Content: White papers, concept briefs, and technical insights detailing design feasibility, integration paths, operational readiness, and sustainment strategies. Summaries of studies performed to date are beneficial.
- Page Limits: Submissions should be no more than five (5) pages. Past performance summaries should be no more than one (1) page.
- Ideal Responses Include: Technical description, summary of relevant experience/past performance, estimated timelines and scalability, sustainment considerations, potential cost drivers, and risk factors for development, FDA licensure, and fielding.
- Submission Portal: Respond via the JETT page:
https://jacks.jpeocbrnd.army.mil/JETT, selecting "Respond to an RFI".
Contract Details
This is an RFI for market research only and does not constitute a Request for Proposal (RFP)/Request for Quote (RFQ). No commitment to contract has been made. Non-response to this RFI does not preclude participation in future solicitations.
Set-Aside
Not applicable for this RFI.